← Back to Clinical Trials
Recruiting NCT05518643

NCT05518643 Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05518643
Status Recruiting
Phase
Sponsor University of Thessaly
Condition ERAS
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2022-07-15
Primary Completion 2025-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
ERAS protocol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2022-07-15 with a primary completion date of 2025-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the impact of compliance with enhanced recovery after surgery (ERAS) program on patient reported outcomes (PROs), surgery-specific outcomes and stress response after pancreatic surgery. This prospective observational study will include all consecutive patients undergoing pancreatic surgery over a period of three years (2022 - 2025) at two sites, namely University General Hospital of Larissa and IASO Thessalias, in Greece. Patients will be prospectively enrolled after written informed consent. Data will be collected on patient characteristics, surgical and anaesthetic techniques, complications, and length of stay. Quality of life questionnaires will be administered to patients preoperatively, on the fith postoperative day, first follow-up after discharge, one month and six months after the operation. The stress response will be assessed by measuring the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio (NLR and PLR) preoperatively, and on the first five postoperative days. Data will be collected on pancreatic surgery-specific complications such as delayed gastric emptying (DGE), post-pancreatectomy haemorrhage (PPH) and postoperative pancreatic fistula (POPF) formation. Anonymised data will be uploaded by the principal investigator on a protected excel spreadsheet for analysis.

Eligibility Criteria

Inclusion Criteria: * all pancreatic surgery patients * above the age of 18 * fluent greek speakers * without communication barriers Exclusion Criteria: * younger than 18 years-old * unable or unwilling to participate * other surgical procedures * communication barriers * lost to follow-up

Contact & Investigator

Central Contact

Despoina Liotiri, Consultant

✉ deppieliotiri@gmail.com

📞 00306947941422

Principal Investigator

Despoina Liotiri, Consultant

PRINCIPAL INVESTIGATOR

University of Thessaly, IASO Thessalias

Frequently Asked Questions

Who can join the NCT05518643 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying ERAS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05518643 currently recruiting?

Yes, NCT05518643 is actively recruiting participants. Contact the research team at deppieliotiri@gmail.com for enrollment information.

Where is the NCT05518643 trial being conducted?

This trial is being conducted at Larissa, Greece.

Who is sponsoring the NCT05518643 clinical trial?

NCT05518643 is sponsored by University of Thessaly. The principal investigator is Despoina Liotiri, Consultant at University of Thessaly, IASO Thessalias. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology